EDAP TMS S.A. (EDAP)'s Ablatherm-HIFU Demonstrates Long Term Efficacy, Durability and Reproducibility With Prospective Fourteen -Year Study
5/20/2013 9:37:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LYON, France, May 20, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today new long term data demonstrating high rates of both cancer-specific and overall survival of patients treated with high-intensity focused ultrasound (HIFU). The study led by Drs. Sebastien Crouzet and Albert Gelet of Edouard Herriot Hospital, located in Lyon, France evaluated the morbidity and long term oncologic outcomes of primary HIFU therapy for localized prostate cancer. The prospective, single-arm, single-institution cohort study was electronically published by European Urology, the official journal of the European Association of Urology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by